COPD (With - Without Rehabilitation)NCT07752420
Effects of Structural Integration on Chest Wall Expansion Among COPD Patients
A study testing Structural Integration with Conventional Pulmonary Rehabilitation and Pulmonary Rehabilitation only in people with COPD (With - Without Rehabilitation), run by Green International University at 1 site in Pakistan.
Trial summary
The present study aims to investigate the effects of the 10-Series of Structural Integration on chest wall expansion in patients with stable COPD using a randomized controlled trial design. Read more about this study
- Who is it for?
- Ages 50 to 70 years
- Conditions the study is for
- COPD (With - Without Rehabilitation)
- What is being tested?
- Structural Integration with Conventional Pulmonary Rehabilitation and Pulmonary Rehabilitation only
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 52 participants
- Where
- 1 sitePakistan
- Study dates
- 1 Sep 2026to 30 Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 to 70 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Clinically diagnosed stable COPD according to GOLD criteria
- GOLD stage II or III
- No acute exacerbation within the previous four weeks
- Able to ambulate independently
- Medically cleared to participate in pulmonary rehabilitation
- Willing to provide written informed consent
Who cannot join
- Severe cardiovascular disease contraindicating exercise
- Recent thoracic or abdominal surgery (<6 months)
- Rib fractures or severe chest wall deformity
- Neurological disorders affecting mobility
- Active malignancy
- Severe osteoporosis with high fracture risk
- Previous Structural Integration treatment within the last year
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Effects of "The 10-Series of Structural Integration" on Chest Wall Expansion Among COPD Patients
The present study aims to investigate the effects of the 10-Series of Structural Integration on chest wall expansion in patients with stable COPD using a randomized controlled trial design. Participants receiving Structural Integration in addition to conventional pulmonary rehabilitation will be compared with those receiving conventional pulmonary rehabilitation alone. Chest wall expansion will serve as the primary outcome, while pulmonary function, dyspnea, functional exercise capacity, and quality of life may be evaluated as secondary outcomes.
- Conditions
- COPD (With - Without Rehabilitation)
- Being tested
- Structural Integration with Conventional Pulmonary Rehabilitation, Pulmonary Rehabilitation only
- Keywords
- COPD, Structural Integration, Chest Wall Expansion, Pulmonary Rehabilitation
- Medical subject headings
- Pulmonary Disease, Chronic Obstructive
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Structural Integration with Conventional Pulmonary RehabilitationOther
- Conventional pulmonary rehabilitation.
- The complete 10-Series of Structural Integration, delivered by a certified Structural Integration practitioner/physiotherapist.
Pulmonary Rehabilitation onlyOther
Participants receive only the conventional pulmonary rehabilitation program.
| Study group | Role | What they receive |
|---|---|---|
| Experimental Group | Experimental | Not described Receives: Other: Structural Integration with Conventional Pulmonary Rehabilitation |
| Control Group | Active comparator | Not described Receives: Other: Pulmonary Rehabilitation only |
What is being measured
The primary outcome is the main question the study is designed to answer.
Chest Wall Expansion
Chest wall expansion will be measured using a flexible measuring tape at:
- Axillary level
- Xiphoid level
- Lower thoracic level (10th rib) Measurements will be taken during maximal inspiration and maximal expiration. The difference (in centimeters) will be recorded. Three readings will be obtained at each level, and the average value will be used for analysis.
Measured: Before the start and end of 10 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Aug 2026
- Study start1 Sep 2026
- Primary completion15 Nov 2026 (estimated)
- Study completion30 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for COPD (With - Without Rehabilitation)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 52 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Green International University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Mohtishim Ahmed, Green International University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07752420
- Sponsor's protocol ID
- GIU/IRB/110047-1
- Status last verified
- Oct 2026
- First submitted
- 4 Aug 2026
- Last updated
- 13 Oct 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: The details will be provided to researchers subject to reason of IPD requirement. The record will be provided through Email. Only official Emails will be entertained.
Study at a glance
From the registry record, last updated by the sponsor on 13 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effects of "The 10-Series of Structural Integration" on Chest Wall Expansion Among COPD Patients
- ClinicalTrials.gov ID
- NCT07752420
- Acronym / sponsor ID
- GIU/IRB/110047-1
- Conditions
- COPD (With - Without Rehabilitation)
- Keywords
- COPD, Structural Integration, Chest Wall Expansion, Pulmonary Rehabilitation
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 52 participants (estimated)
- Lead sponsor
- Green International UniversityUniversity, hospital or other
- Study start
- 1 Sep 2026 (actual)
- Primary completion
- 15 Nov 2026 (estimated)
- Study completion
- 30 Dec 2026 (estimated)
- First posted
- 7 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The present study aims to investigate the effects of the 10-Series of Structural Integration on chest wall expansion in patients with stable COPD using a randomized controlled trial design. Participants receiving Structural Integration in addition to conventional pulmonary rehabilitation will be compared with those receiving conventional pulmonary rehabilitation alone. Chest wall expansion will serve as the primary outcome, while pulmonary function, dyspnea, functional exercise capacity, and quality of life may be evaluated as secondary outcomes.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Experimental Group | Experimental | Other: Structural Integration with Conventional Pulmonary Rehabilitation |
| Control Group | Active comparator | Other: Pulmonary Rehabilitation only |
Who may qualify
- Ages
- 50 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Clinically diagnosed stable COPD according to GOLD criteria
- GOLD stage II or III
- No acute exacerbation within the previous four weeks
- Able to ambulate independently
- Medically cleared to participate in pulmonary rehabilitation
Key exclusion criteria (7 listed)
- Severe cardiovascular disease contraindicating exercise
- Recent thoracic or abdominal surgery (<6 months)
- Rib fractures or severe chest wall deformity
- Neurological disorders affecting mobility
- Active malignancy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Structural Integration with Conventional Pulmonary Rehabilitation* Conventional pulmonary rehabilitation. * The complete 10-Series of Structural Integration, delivered by a certified Structural Integration practitioner/physiotherapist. | Other | Experimental Group |
| Pulmonary Rehabilitation onlyParticipants receive only the conventional pulmonary rehabilitation program. | Other | Control Group |
Primary outcome
Chest Wall Expansion
Time frame: Before the start and end of 10 weeks
Chest wall expansion will be measured using a flexible measuring tape at: * Axillary level * Xiphoid level * Lower thoracic level (10th rib) Measurements will be taken during maximal inspiration and maximal expiration. The difference (in centimeters) will be recorded. Three readings will be obtained at each level, and the average value will be used for analysis.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Oct 2026.
- Individual participant dataSharing planned: Yes. The details will be provided to researchers subject to reason of IPD requirement. The record will be provided through Email. Only official Emails will be entertained.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Structural Integration with Conventional Pulmonary Rehabilitation and Pulmonary Rehabilitation only in people with COPD (With - Without Rehabilitation), run by Green International University at 1 site in Pakistan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 13 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Pakistan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Chest Wall Expansion (time frame: Before the start and end of 10 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Oct 2026.